期刊文献+

加味消渴方治疗初发2型糖尿病的临床疗效观察 被引量:8

下载PDF
导出
摘要 目的探索加味消渴方联合胰岛素强化治疗对初发2型糖尿病(阴虚热盛型)的临床疗效观察。方法选择在该院2013年1月—2017年1月期间内对治疗的292例初发2型糖尿病,中医辨证为阴虚热盛型消渴病患者按照两组患者随机分为人数各为146例的对照组和实验组。对照组采用的是常规的基础治疗+胰岛素强化治疗,实验组则在此基础上再联合加味消渴方汤剂口服治疗,两周为1个疗程。结果对照组患者最终的治疗证候积分为(13.70±5.29)分,实验组的最终证候积分为(6.23±5.05)分,实验组患者的证候积分比对照组患者的低,差异有统计学意义(P<0.05)。实验组血糖达标时间为(6.3±1.8)d,对照组血糖达标时间为(7.9±1.7)d,实验组血糖达标时间明显低于对照组,差异有统计学意义(P<0.05)。结论胰岛素强化治疗联合加味消渴方治疗阴虚热盛型糖尿病的效果显著,起效快,副作用小,安全可靠,可有效缓解患者临床症状,迅速改善患者生活质量,值得在临床上推广。
作者 夏正芹 戴林
出处 《糖尿病新世界》 2017年第11期93-94,共2页 Diabetes New World Magazine
  • 相关文献

参考文献6

二级参考文献30

  • 1Jean Claude Mbanya. A Call to Action on Diabetes[R]. International Diabetes Federation, 2010, 11 : 2.
  • 2Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12): 1090-1101.
  • 3World Health Organization. Preventing Chromic Diseases: A Vital Investment. World Health Organization. Geneva[Z]. 2005.
  • 4Palmer AJ, Roze S, Valentine W J, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making[J]. Curr Med Res Opin, 2004, 20 (Suppl 1): S5-S26.
  • 5Miller DR, Gardner JA, Hendricks AM, et al. Health care resource utilization and expenditures associated with the use of insulin glargine[J]. Clin Ther, 2007, 29(3): 478-487.
  • 6Bullano MF, AI-Zakwani IS, Fisher MD, et al. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products[J]. Curr Med Res Opin, 2005, 21(2): 291-298.
  • 7Brandle M, Azoulay M, Greiner RA. Cost-effectiveness and cost- utility of insulin glargine compared with NPH insulin based on a 10- year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland[J]. lnt J Clin Pharmacol Ther, 2007, 45(4): 203-220.
  • 8Valentine W J, Goodall G, Aagren M, et al. Evaluating the cost- effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes[J]. Adv Yher, 2008, 25(6): 567-584.
  • 9Valentine W J, Emy-Albrecht KM, Ray JA, et al. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States[J]. Adv Ther, 2007, 24(2): 273-290.
  • 10Gschwend MH, Aagren M, Valentine WJ. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries[J]. J Med Econ, 2009, 12(2): 114-123.

共引文献168

同被引文献104

引证文献8

二级引证文献75

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部